Swiss buy is too high, say analysts

Davis, Nigel
September 2006
ICIS Chemical Business;9/25/2006, Vol. 1 Issue 36, p8
Trade Publication
This article reports on the decision of Merck KGaA to acquire Swiss biopharmaceuticals company Serono. According to analysts, Merck KGaA shares fell nearly 6% on the news. The acquisition of Serono would transform Merck's ethical pharmaceuticals business and create a leader in biological medicines. Merck KGaA said its acquisition of family-held Serono would transform its ethical pharmaceuticals business and create a leader in biological medicines.


Related Articles

  • Merck KGaA Launches Merck Serono SA and Plans to Divest Generics Business. Van Arnum, Patricia // Pharmaceutical Technology;Feb2007, Vol. 31 Issue 2, p26 

    The article presents various developments in the pharmaceutical operation of Merck KGaA. The company has completed its acquisition of the majority stake of Serono SA. On the other hand, the company announces that it is considering the divestiture of Merck Generics. Meanwhile, it is planning to...

  • German M&A continues apace. Williams, Dede; Gibson, Jane // ICIS Chemical Business;10/2/2006, Vol. 1 Issue 37, p10 

    The article reports on the plan of Merck KGaA to acquire 64.5% of equity and 75.5% of voting rights of Swiss biopharmaceuticals producer Serono for €10.6 billion. After incorporating Serono, Merck will have overall sales of €7.7 billion, including €3.6 billion in...

  • MERCK KGAA COMPLETED. Arnold, Matthew // Medical Marketing & Media;Feb2007, Vol. 42 Issue 2, p12 

    The article reports on the completion of the acquisition made by Merck KGaA to Serono SA and launches it as Merck Serono SA in Geneva, Switzerland. The firm increases its European marketing rights to Erbitux and co-markets Rebif with Pfizer. The company selected Elmar Schnee to serve as CEO for...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Feb2007, Vol. 6 Issue 2, p3 

    The article offers news briefs related to the pharmaceutical industry. Merck KGaA has launched Merck Serono as subsidiary following its takeover of Swiss biotech company Serono SA. MedImmune Inc. has won the right to challenge a patent held by Genentech Inc. while continuing to pay the latter's...

  • Merck KGaA Confirms Generics Sale; Launches Merck Serono. Scott, Alex // Chemical Week;1/17/2007, Vol. 169 Issue 2, p23 

    The article considers the decision of Merck KGaA to evaluate the divestiture of its Merck Generics generic drug division. The company confirmed that it is in the early stages of planning to sell the generics business, and that it is not engaged in initial discussions with any potential buyers....

  • Merck KGaA to Acquire Serono for Over $13 Billion. Young, Ian // Chemical Week;9/27/2006, Vol. 168 Issue 32, p8 

    The article reports on the plan of chemical firm Merck KGaA to purchase European biotechnology firm Serono. Merck has agreed to acquire the Bertarelli family's stake in Serono. Merck will initially pay with cash and bridge financing. Merck will combine its pharma ethicals division with Serono to...

  • Biotechs Must Look Good To Capitalize On Market.  // Bioworld Week;5/14/2007, Vol. 15 Issue 20, p5 

    The article reports on the increase of the merger and acquisition deals within the biotechnology industries in the U.S. It is stated that acquisition is one of the strategic plans of companies for market penetration. It has been indicated that there are more than 300 merger and acquisition deals...

  • NovImmune Raises $56.5M to Broaden Antibody Pipeline. Sheridan, Cormac // BioWorld Today;5/12/2009, Vol. 20 Issue 90, p1 

    The article announces that NovImmune has raised 54.8 U.S. dollars in equity financing to broaden antibody pipeline in 2009. The company is using part of the proceeds to regain control over NI-0401 and NI-0501, two fully human monoclonal antibodies it out-licensed to what was then Serono SA in a...

  • Merck takes on new challenges. Williams, Dede; Gibson, Jane // ICIS Chemical Business;1/15/2007, Vol. 2 Issue 49, p12 

    The article reports on a tender offer launched by Merck KGaA for the outstanding equity of Swiss-based biopharmaceuticals producer Serono. Merck also confirmed tentative plans to sell its generics business. The German drugs and chemicals group now controls 84% of Serono's shares and 89% of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics